Asset Management One Co. Ltd. Makes New $98,000 Investment in Halozyme Therapeutics, Inc. $HALO

Asset Management One Co. Ltd. purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,882 shares of the biopharmaceutical company’s stock, valued at approximately $98,000.

Other hedge funds have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in Halozyme Therapeutics in the first quarter worth $32,000. SVB Wealth LLC bought a new position in shares of Halozyme Therapeutics in the first quarter worth approximately $33,000. Bessemer Group Inc. grew its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the last quarter. Brooklyn Investment Group grew its holdings in shares of Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 670 shares during the last quarter. Finally, CWM LLC grew its holdings in shares of Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 438 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director owned 46,952 shares in the company, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 108,227 shares of company stock worth $7,779,595 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $64.63 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $79.50. The stock has a market cap of $7.56 billion, a PE ratio of 14.79, a price-to-earnings-growth ratio of 0.35 and a beta of 1.16. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The company’s fifty day moving average price is $71.30 and its 200-day moving average price is $62.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. During the same quarter in the previous year, the business posted $0.91 EPS. The company’s quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HALO. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a report on Monday, October 20th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price on the stock. Finally, Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Four research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $73.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.